Internal Reference Number: FOI_9518
Date Request Received: 06/07/2026 00:00:00
Date Request Replied To: 21/07/2026 00:00:00
This response was sent via: By Email
Request Summary: Oncology
Request Category: Researcher
| Question Number 1: How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib | |
| Answer To Question 1: • Atezolizumab (Tecentriq)less than 5 • Durvalumab (Imfinzi)less than 5 • Nivolumab (Opdivo) 0 • Pembrolizumab (Keytruda) 0 • Chemotherapy Less than 5 • Radiotherapy not provided at SFT • Chemotherapy AND Radiotherapy - radiotherapy not provided at SFT • Osimertinib 0 | |
| Question Number 2: How many patients has your Trust treated in total in the past 3 months for • Stage 2 Non-Small Cell Lung Cancer • Stage 3 Non-Small Cell Lung Cancer | |
| Answer To Question 2: • Stage 2 Non-Small Cell Lung Cancer less than 5 • Stage 3 Non-Small Cell Lung Cancer less than 5 | |
| Question Number 3: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab • Pembrolizumab monotherapy • Pembrolizumab monotherapy (subcutaneous injection formulation only) • Pembrolizumab with chemotherapy • Pembrolizumab with chemotherapy (subcutaneous injection formulation only) • Nivolumab • Osimertinib • Durvalumab • Chemotherapy • Radiotherapy • Chemotherapy + Radiotherapy | |
| Answer To Question 3: • Atezolizumab less than 5 • Pembrolizumab monotherapy 0 • Pembrolizumab monotherapy (subcutaneous injection formulation only) 0 • Pembrolizumab with chemotherapy 0 • Pembrolizumab with chemotherapy (subcutaneous injection formulation only) 0 • Nivolumab 0 • Osimertinib 0 • Durvalumab less than 5 • Chemotherapy less than 5 • Radiotherapy not provided at SFT • Chemotherapy + Radiotherapy radiotherapy not provided at SFT | |
| Question Number 4: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with: • Chemotherapy • Radiotherapy • Chemotherapy + Radiotherapy | |
| Answer To Question 4: • Chemotherapy less than 5 • Radiotherapy not provided at SFT • Chemotherapy + Radiotherapy - radiotherapy not provided at SFT | |
| Question Number 5: How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Durvalumab | |
| Answer To Question 5: 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
